Thursday January 24, 2019

Only these 7 pasta brands have been given green chit by FSSAI after Maggi mess

0
//

9682763081_542a55fb84_o

New Delhi: Instant noodles and pastas with taste-makers of only seven companies are allowed to be sold in India, the food safety watchdog said on Monday, while also ordering tests on all approved variants and calling for the remaining “illegal” ones to be destroyed.

The seven companies that have approvals for their variants of instant noodles and pastas with taste-makers are:

FSSAI Approved Pastas & Noodles Companies Are:

  • Ruchi International (Koka)
  • CG Foods (Wai Wai)
  • Glaxosmithkline (Foodles)
  • Nestle (Maggi)
  • AA Nutrition (Yummy)
  • Indo Nisin (Top Ramen)
  • ITC (brand not specified)

“The safety of all other products in these categories has not been assessed as per the product approval procedures. As such, the same are unauthorized and illegal and cannot be intended for human consumption,” said a letter from the Food Safety and Standards Authority of India (FSSAI).

Ordering tests on all the approved varieties, the letter written by chief executive Yudhvir Singh Malik to all the commissioners of food safety said that as far as all the remaining food products are concerned, they are advised to “ensure such products are recalled, removed from the market and destroyed.”

Speaking to IANS, the top food safety officer said tests on Nestle’s Maggi and some other similar products had raised serious health concerns and thus it was thought fit to conduct tests on all similar products for which approvals had been granted.

Following tests on some samples of Maggi, the watchdog on Friday had ordered the recall of all the nine variants of Maggi pan-India, and had asked Nestle to halt its production and exports. It had also issued a similar order on Nestle’s oats noodles and taste-maker.

While Nestle continues to contend that its noodles were safe for humans and that the levels of lead were within permissible limits – as opposed to the findings of some tests that purportedly indicated otherwise, several states also became pro-active by issuing their own ban orders.

“Overseas and local manufacturers would be treated equally. More noodle brands including pasta and macaroni products will also start getting tested this week,” Malik said.

On being asked if the brand ambassadors could be taken to task, he said: “As of now, we are not considering any action.”

The regulator also detailed the process involved in the recall of food products.

“Ideally, consumers should be able to return the product at the retail outlet and get their money back if they have the bill with them. It is also Nestle’s responsibility to let the consumers return their products, if they have kept the bill with them,” he said.

The regulator also plans to post a list of all approved noodle products on its web site and advise the state authorities to test them. “We understand Delhi, Gujarat and Tamil Nadu have already started testing other brands. We will list all the approved noodle products soon.”

He further said that Nestle had been asked to give the regulator an update on compliance first after three days and then regularly until the end. “Because we understand that it could take 10 days or more, we will be taking regular progress reports from the company,” Malik said.

-IANS

Next Story

Protein Identified Enables New Drugs to Increase ‘Good Cholesterol’ Levels

Importantly, ORP2 could also be targeted to fight cancer. 

0
ORP2 could offer a new strategic line of research and possibly succeed where the use of statins in this area hasn't, Yang noted.

Researchers have identified a protein, known as ORP2, responsible for transporting cholesterol inside cells that opens the way for new drugs to increase the body’s ‘good cholesterol’ levels.

ORP2 can increase the amount of cholesterol in cells, a process called cholesterol efflux. We think this pathway will be very important for the development of a drug to increase this good cholesterol, said Rob Yang, Professor from the University of New South Wales in Australia.

Until now, drugs including statins have targeted bad cholesterol (LDL) by inhibiting its synthesis in the liver in an effort to mitigate the risk of heart disease and stroke.

However, while statins are effective at lowering LDL levels, they do little to increase the levels of good cholesterol (HDL) and there is no other drug in use that can significantly boost the human body’s HDL levels.

Congo
Researchers have identified a protein, known as ORP2, responsible for transporting cholesterol inside cells that opens the way for new drugs to increase the body’s ‘good cholesterol’ levels. . VOA

Up to 90 per cent of a cell’s cholesterol is found at the cell’s plasma membrane, said the study published in the journal Molecular Cell.

“Knowing the molecules that deliver cholesterol to the plasma membrane itself is a huge step forward. The transport of cholesterol to the plasma membrane is the key to the generation of HDL.

If such a drug could be developed, it would not replace statins, but would be used complementarily, with one drug used to reduce the bad cholesterol and the other to increase levels of the good, Yang suggested.

Also Read: Number of Students Opting for Science or Tech Are On Rise in India

Importantly, ORP2 could also be targeted to fight cancer.

Cancer, U.S.

Importantly, ORP2 could also be targeted to fight cancer.

The rampant and uncontrolled growth of cells that characterises cancer could be stopped in its tracks by reducing the amount of cholesterol produced.

ORP2 could offer a new strategic line of research and possibly succeed where the use of statins in this area hasn’t, Yang noted. (IANS)